A Study of the HS-20093 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3,
a target wildly expressed on solid tumor cells. The objectives of this study are to
investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in
Chinese advanced solid tumor patients.
This is a phase 1, open-label, multi-center, dose-escalation and expansion study evaluating
the safety, tolerability, pharmacokinetic (PK), and the therapeutic potential of HS-20093 as
a monotherapy in subjects with advanced solid tumors.